정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2151 | Not yet recruiting | Assessment of SARS-CoV-2 Seroprevalence in Detention | COVID-19 | Biological: Blood draw | Not Applicable | Assistance Publique - Hopitaux de Paris | OTHER | 2500 | All | 18 Years ~ 80 Years | |
2150 | Recruiting | Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection | COVID19 | Biological: Convalescent Plasma Drug: Standard of Care |
Phase 2 | Cairo University | OTHER | 67 | All | 21 Years ~ 70 Years | Cairo University Hospital, Cairo, Egypt |
2149 | Withdrawn | Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals | Healthcare Worker | Drug: Hydroxychloroquine (HCQ) Drug: Placebo oral tablet |
Phase 3 | Abderrahmane Mami Hospital, Eshmoun Clinical Research Centre, Datametrix | OTHER | 0 | All | 18 Years ~ 65 Years | Eshmoun Clinical Research Centre/ Hopital Abderrahmane Mami-Ariana, Tunis, Tunisia |
2148 | Not yet recruiting | Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) | COVID19 | Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment Drug: Isotretinoin (13 cis retinoic acid ) capsules Drug: Aerosolized 13 cis retinoic acid Drug: Standard treatment |
Phase 3 | Kafrelsheikh University, 1-Foshan University Laboratory of Emerging Infectious Disease Institute of Translational Medicine The First Hospital of Jilin University China, 2-Montefiore Health System and Albert Einstein College of Medicine, Newyork, United States of America (U.S.A)., 2-Faculty of Science, Kafrelsheikh University, Egypt. | OTHER | 100000 | All | 18 Years ~ 80 Years | Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt |
2147 | Recruiting | Asunercept in Patients With Severe COVID-19 | Covid19 | Biological: Asunercept | Phase 2 | Apogenix AG | INDUSTRY | 400 | All | 18 Years | Republican Clinical Infectious Hospital n.a. professor A.F. Agafonov, Kazan, Russian Federation Scientific Research lnstitute fоr Соmрlех lssues of Cardiovascular Diseases, Kemerovo, Russian Federation Federal State Budgetary Educational Institution of Higher Education "Kuban State Medical University" of the Ministry of Health of the Russian Federation, Krasnodar, Russian Federation State Budgetary Healthcare Institution "Scientific Research Institute - Regional clinical hospital No. 1 n.a. professor S.V. Ochapovsky" of the Ministry of Healthcare of Krasnodar Krai, Krasnodar, Russian Federation Kursk Regional Clinical Hospital, Kursk, Russian Federation State Budgetary Institution of Health of the Nizhny Novgorod Region "Infectious Clinical Hospital No. 2 of Nizhny Novgorod", Nizhny Novgorod, Russian Federation Ryazan State Medical University n.a. academician I.P. Pavlov, Ryazan, Russian Federation Saint Petersburg state budgetary healthcare institution "City hospital of Saint George the great Martyr", Saint Petersburg, Russian Federation Hospital Universitario Infanta Leonor, Madrid, Spain Hospital Universitario La Paz, Madrid, Spain Hospital Universitario Ramon y Cajal, Madrid, Spain Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain Hospital Universitario Infanta Sofia, San Sebastian De Los Reyes, Spain Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain |
2146 | Withdrawn | Asymptomatic COVID-19 Trial | SARS-CoV-2 Infection | Drug: Hydroxychloroquine sulfate &Azithromycin Drug: Placebo |
Phase 2 | Rutgers, The State University of New Jersey | OTHER | 0 | All | 20 Years | Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States |
2145 | Recruiting | AT1001 for the Treatment of COVID-19 Related MIS-C | Multisystem Inflammatory Syndrome in Children | Drug: Larazotide Acetate Drug: Placebo |
Phase 2 | Massachusetts General Hospital | OTHER | 20 | All | 1 Month ~ 21 Years | Massachusetts General Hospital, Boston, Massachusetts, United States |